Saar Gill

Saar Gill at the University of Pennsylvania specializes in universal allogeneic CAR-T development for off-the-shelf clinical use. He uses CRISPR gene editing to delete HLA and T cell receptor genes in donor T cells, creating universal CAR-T products that avoid graft-versus-host disease. His work on myeloid-targeting CAR-T cells for AML is particularly innovative given the target antigen challenges in this disease.